Laura Sepp-Lorenzino, EVP, Chief Scientific Officer at Intellia Therapeutics, Inc. (NTLA), sold 193,793 shares at $153.64 ($30.0M) on 2021-08-30, disclosed to the SEC on 2021-09-01.
Open-market sale of $30.0M NTLA by EVP, Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $152.75 | 15,839 | $2.4M | 8.1% |
| 2 | $152.75 | 15,839 | $2.4M | 8.1% |
| 3 | $153.64 | 20,645 | $3.2M | 10.6% |
| 4 | $153.64 | 20,645 | $3.2M | 10.6% |
| 5 | $154.77 | 28,669 | $4.4M | 14.8% |
| 6 | $154.77 | 28,669 |
| $4.4M |
| 14.8% |
| 7 | $155.61 | 16,115 | $2.5M | 8.4% |
| 8 | $155.61 | 16,115 | $2.5M | 8.4% |
| 9 | $156.79 | 7,425 | $1.2M | 3.9% |
| 10 | $156.79 | 7,425 | $1.2M | 3.9% |
| 11 | $157.77 | 3,932 | $620K | 2.1% |
| 12 | $157.77 | 3,932 | $620K | 2.1% |
| 13 | $158.90 | 1,515 | $241K | 0.8% |
| 14 | $158.90 | 1,515 | $241K | 0.8% |
| 15 | $159.64 | 2,653 | $424K | 1.4% |
| 16 | $159.64 | 2,653 | $424K | 1.4% |
| 17 | $160.47 | 207 | $33K | 0.1% |
| Total | $154.82 avg | 193,793 | $30.0M | 100% |
| Filing → |
| NTLA | SELL | 2024-01-05 | $326K | — | Filing → |
| NTLA | SELL | 2023-01-06 | $339K | — | Filing → |
| NTLA | SELL | 2022-03-03 | $129K | — | Filing → |